Search details
1.
Improvement of early-phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study.
Diabetes Obes Metab
; 26(2): 745-753, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37985364
2.
Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
Diabetes Obes Metab
; 26(4): 1197-1206, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38172083
3.
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Diabetes Obes Metab
; 2024 Apr 15.
Article
in English
| MEDLINE | ID: mdl-38618970
4.
Expression patterns of mechanosensitive ion channel PIEZOs in irreversible pulpitis.
BMC Oral Health
; 24(1): 465, 2024 Apr 16.
Article
in English
| MEDLINE | ID: mdl-38627713
5.
Exploring high-resolution chromatin interaction changes and functional enhancers of myogenic marker genes during myogenic differentiation.
J Biol Chem
; 298(8): 102149, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35787372
6.
iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
Diabetes Obes Metab
; 25(7): 2005-2011, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36999231
7.
Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS).
Diabetes Obes Metab
; 25(1): 272-281, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36099069
8.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Diabetes Obes Metab
; 24(8): 1522-1533, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35441412
9.
PRDX6 alleviates lipopolysaccharide-induced inflammation and ferroptosis in periodontitis.
Acta Odontol Scand
; 80(7): 535-546, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35723029
10.
Genetic mapping high protein content QTL from soybean 'Nanxiadou 25' and candidate gene analysis.
BMC Plant Biol
; 21(1): 388, 2021 Aug 20.
Article
in English
| MEDLINE | ID: mdl-34416870
11.
Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab
; 23(2): 642-647, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33074590
12.
Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial.
Diabetes Obes Metab
; 23(1): 116-124, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32965075
13.
Gender-differential effects on blood glucose levels between acarbose and metformin in Chinese patients with newly diagnosed type 2 diabetes: a sub-analysis of the MARCH trial.
Endocr J
; 68(1): 69-79, 2021 Jan 28.
Article
in English
| MEDLINE | ID: mdl-32908086
14.
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Hepatology
; 69(6): 2414-2426, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30341767
15.
Early-onset type 2 diabetes is associated with genetic variants of ß-cell function in the Chinese Han population.
Diabetes Metab Res Rev
; 36(2): e3214, 2020 02.
Article
in English
| MEDLINE | ID: mdl-31465628
16.
Prevalences and associated factors of electrocardiographic abnormalities in Chinese adults: a cross-sectional study.
BMC Cardiovasc Disord
; 20(1): 414, 2020 09 11.
Article
in English
| MEDLINE | ID: mdl-32917144
17.
Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial.
Diabetes Obes Metab
; 21(8): 1973-1977, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30938035
18.
Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Diabetes Obes Metab
; 21(7): 1652-1660, 2019 07.
Article
in English
| MEDLINE | ID: mdl-30869183
19.
Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: A population-based multicentre nationwide survey.
Diabetes Obes Metab
; 21(4): 893-902, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30471182
20.
Comparison of therapeutic effects of acarbose and metformin under different ß-cell function status in Chinese patients with type 2 diabetes.
Endocr J
; 66(5): 443-450, 2019 May 28.
Article
in English
| MEDLINE | ID: mdl-30944269